Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Incyte Corp (INCY)

Incyte Corp (INCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Is Wall Street Bullish or Bearish on Incyte Stock?

Wilmington, Delaware-based Incyte Corporation (INCY) is a biopharmaceutical company that discovers, develops, and commercializes therapeutics for serious medical needs. Valued at a market cap of $12.3 billion, the company's primary focus areas include oncology, inflammation, and autoimmunity. 

This biotech company has underperformed the broader market over the past 52 weeks. Shares of INCY have gained 11.3% over this time frame, while the broader S&P 500 Index ($SPX) has soared 12.5%. Moreover, on a YTD basis, the stock is down 8.3%, compared to SPX’s 1.3% uptick. 

Nonetheless, narrowing the focus, INCY has outpaced the iShares Biotechnology ETF’s (IBB) 11.8% loss over the past 52 weeks and...

Fundamentals

See More
  • Market Capitalization, $K 12,254,918
  • Shares Outstanding, K 193,570
  • Annual Sales, $ 4,241 M
  • Annual Income, $ 32,610 K
  • EBIT $ 175 M
  • EBITDA $ 264 M
  • 60-Month Beta 0.68
  • Price/Sales 2.86
  • Price/Cash Flow 113.37
  • Price/Book 3.31

Options Overview Details

View History
  • Implied Volatility 33.12% ( +1.35%)
  • Historical Volatility 38.75%
  • IV Percentile 44%
  • IV Rank 31.91%
  • IV High 63.71% on 03/11/25
  • IV Low 18.78% on 05/23/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 115
  • Volume Avg (30-Day) 486
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 14,359
  • Open Int (30-Day) 21,960

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate 1.11
  • Number of Estimates 8
  • High Estimate 1.18
  • Low Estimate 1.05
  • Prior Year -2.03
  • Growth Rate Est. (year over year) +154.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
56.13 +12.85%
on 04/21/25
64.30 -1.49%
on 05/19/25
+5.13 (+8.81%)
since 04/17/25
3-Month
53.56 +18.26%
on 04/09/25
76.24 -16.92%
on 02/25/25
-6.82 (-9.72%)
since 02/19/25
52-Week
53.56 +18.26%
on 04/09/25
83.95 -24.55%
on 11/08/24
+6.24 (+10.93%)
since 05/17/24

Most Recent Stories

More News
Is Wall Street Bullish or Bearish on Incyte Stock?

Despite Incyte’s underperformance relative to the S&P 500 over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

BAC : 44.69 (+0.01%)
$SPX : 5,954.09 (-0.07%)
IBB : 121.91 (+0.62%)
INCY : 63.34 (+0.05%)
INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales

Incyte Corporation INCY reported first-quarter 2025 adjusted earnings of $1.16 per share, which beat the Zacks Consensus Estimate of $1.01. The company had recorded adjusted earnings of 58 cents per share...

BAYRY : 6.5100 (+2.20%)
LLY : 750.46 (-0.91%)
INCY : 63.34 (+0.05%)
NVS : 110.19 (+0.55%)
3 Value Stocks Facing Headwinds

3 Value Stocks Facing Headwinds

CARS : 10.78 (-1.55%)
MTCH : 29.60 (+1.20%)
INCY : 63.34 (+0.05%)
3 Value Stocks Facing Headwinds

3 Value Stocks Facing Headwinds

CARS : 10.78 (-1.55%)
MTCH : 29.60 (+1.20%)
INCY : 63.34 (+0.05%)
Incyte (NASDAQ:INCY) Delivers Strong Q1 Numbers

Incyte (NASDAQ:INCY) Delivers Strong Q1 Numbers

INCY : 63.34 (+0.05%)
Incyte (NASDAQ:INCY) Delivers Strong Q1 Numbers

Incyte (NASDAQ:INCY) Delivers Strong Q1 Numbers

INCY : 63.34 (+0.05%)
Incyte: Q1 Earnings Snapshot

Incyte: Q1 Earnings Snapshot

INCY : 63.34 (+0.05%)
Incyte (INCY) Q1 Earnings Report Preview: What To Look For

Incyte (INCY) Q1 Earnings Report Preview: What To Look For

INCY : 63.34 (+0.05%)
ABBV : 185.28 (+0.68%)
GILD : 105.36 (+2.79%)
3 Cash-Heavy Stocks Skating on Thin Ice

3 Cash-Heavy Stocks Skating on Thin Ice

MOV : 17.09 (-1.50%)
INCY : 63.34 (+0.05%)
SONO : 10.57 (-2.94%)
Incyte Earnings Preview: What to Expect

Incyte is all set to release its fiscal first-quarter earnings later this month, and analysts project a high double-digit profit growth.

XLV : 133.85 (+0.57%)
$SPX : 5,954.09 (-0.07%)
INCY : 63.34 (+0.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2...

See More

Key Turning Points

3rd Resistance Point 64.37
2nd Resistance Point 63.92
1st Resistance Point 63.62
Last Price 63.34
1st Support Level 62.87
2nd Support Level 62.42
3rd Support Level 62.12

See More

52-Week High 83.95
Fibonacci 61.8% 72.34
Fibonacci 50% 68.75
Fibonacci 38.2% 65.17
Last Price 63.34
52-Week Low 53.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar